Cardiovascular disease has emerged as a critical consideration in cancer survivorship, with many cancer therapies carrying both short- and long-term cardiac implications. In this session, Dr. Susan Dent will review key principles in cardio-oncology, including treatment-related cardiotoxicity, risk assessment, surveillance strategies, and multidisciplinary management of patients during and after cancer therapy. Designed for clinicians, this discussion will provide practical, evidence-based guidance to support the early identification, prevention, and management of cardiovascular complications in patients with cancer.

Susan Dent, MD, FRCPC, completed her medical degree at McMaster University in Hamilton, Ontario, followed by residency training in Internal Medicine and Medical Oncology at The Ottawa Hospital, University of Ottawa, and a postgraduate research fellowship in clinical trials with the Canadian Cancer Trials Group in Kingston, Ontario, before serving as staff medical oncologist in Thunder Bay. She returned to Ottawa in 2001 to specialize in breast cancer with a focus on new drug development, and in 2008 established a multidisciplinary cardio-oncology clinic, later founding the Canadian Cardiac Oncology Network in 2011 and launching the Global Cardio-Oncology Summit in 2015, now attended by clinicians from over 23 countries. From 2018 to 2024, Dr. Dent held a staff position at Duke University as Associate Director of Breast Cancer Clinical Research and Co-Director of the Duke Cardio-Oncology Program. Internationally recognized as a global leader in cardio-oncology, she focuses on evaluating novel breast cancer therapies while advancing understanding of their cardiovascular effects, and she has collaborated extensively with major global oncology and cardiology organizations. She currently serves as President of the International Cardio-Oncology Society and, as of September 2024, holds a staff position at the University of Rochester as a breast cancer medical oncologist, Director of Cardio-Oncology, and Director of Survivorship at the Wilmot Cancer Institute.